Involvement of 5-HT3 receptors in the development and expression of methamphetamine-induced behavioral sensitization:: 5-HT3A receptor channel and binding study

Methamphetamine (MAP) is one of the most commonly abused drugs in Asia, and previous studies suggest that serotonin 3 receptors (5-HT3) are involved in MAP-induced locomotion and reward. However, little is known about the role of 5-HT3 receptors in MAP-induced behavioral sensitization. Here, we measured the effects of MDL 72222, a 5-HT3 antagonist, and SR 57227 A, a 5-HT3 agonist, on the development and expression of MAP-induced behavioral sensitization, and alternations of 5-HT3 receptor binding labeled with the 5-HT3-selective antagonist, [H-3]GR65630, in mice. In addition, we investigated the effects of MAP on 5-HT3A receptor channel activity in Xenopus laevis oocytes expressing 5-HT3A receptors. We found that MDL 72222 attenuated both the development and expression of behavioral sensitization to MAP (1.0 mg/kg, i.p.), and that this attenuating effect of MDL 72222 was reversed by pre-treatment with SR 57227 A. In oocytes expressing 5-HT3A receptor, MAP exhibited a dual modulation of 5-HT3A receptor channel activity, i.e. pre-treatment with a low dose of MAP (0.1 mu M) enhanced 5-HT-induced inward peak current (I5-HT) but a high dose of MAP (100 mu M) inhibited I5-HT. The acute administration of MDL 72222 with MAP decreased [H-3]GR65630 binding versus MAP alone in the mouse striatum. Our results suggest that MDL 72222 attenuates MAP-induced behavioral sensitization via 5-HT3 receptors in the caudate putamen, and that 5-HT3 receptor antagonists like MDL 72222 have potential as novel anti-psychotic agents for the treatment of MAP dependence and psychosis.